FDA Panel Recommends Easing Restrictions on Several Peptides The US Food and Drug Administration's Pharmacy Compounding Advisory Committee recently voted to ease restrictions on several peptides, sparking debate among medical professionals and regulators.
Proponents argue that this move will bring legitimacy and safety to a burgeoning industry, while critics warn of potential risks and unintended consequences.
At the heart of the controversy are the peptides themselves, whose chemical composition is still unclear. As FDA official Russell Wesdyk noted, "We've never faced a problem of, 'What is it?